Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

Y0001018

Cisplatin impurity A

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

trans-Platinum(II)diammine dichloride, trans-Diamminedichloroplatinum(II), trans-Dichlorodiammineplatinum(II)

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula linear:
Pt(NH3)2Cl2
Número CAS:
14913-33-8
Peso molecular:
300.05
Número MDL:
MFCD00011623
Código UNSPSC:
41116107
ID de substância PubChem:
329831221
NACRES:
NA.24
Preço e disponibilidade não estão disponíveis no momento.

grau

pharmaceutical primary standard

família API

cisplatin

fabricante/nome comercial

EDQM

pf

340 °C (dec.) (lit.)

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

N.N.Cl[Pt]Cl

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

chave InChI

LXZZYRPGZAFOLE-UHFFFAOYSA-L

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Cisplatin impurity A EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

C2210000

Cisplatin, European Pharmacopoeia (EP) Reference Standard

Y0001019

Cisplatin impurity B, European Pharmacopoeia (EP) Reference Standard

1551300

Potassium Trichloroammineplatinate, United States Pharmacopeia (USP) Reference Standard

1672803

Transplatin, United States Pharmacopeia (USP) Reference Standard

1134357

Cisplatin, United States Pharmacopeia (USP) Reference Standard

PHR1624

Cisplatin, Pharmaceutical Secondary Standard; Certified Reference Material

BP809

Cisplatin, British Pharmacopoeia (BP) Reference Standard

BP510

Potassium trichloroammineplatinate, British Pharmacopoeia (BP) Reference Standard

BP544

Transplatin, British Pharmacopoeia (BP) Reference Standard

PHR3252

Transplatin, pharmaceutical secondary standard, certified reference material

Pictogramas

Health hazardCorrosion
GHS08,GHS05

Palavra indicadora

Danger

Frases de perigo

H317,H318,H334

Classificações de perigo

Eye Dam. 1 - Resp. Sens. 1 - Skin Sens. 1

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Yuniardini S Wimardhani et al.
Journal of oral science, 56(2), 119-126 (2014-06-17)
Chitosan, a multipurpose biomaterial, has been shown to exert effects against several types of cancer including oral cancer. However, the mechanisms underlying the anticancer activities of chitosan on oral squamous cell carcinoma (SCC) cells remain largely unknown. The present study
Michelle X Liu et al.
Oncotarget, 5(4), 944-958 (2014-03-25)
Epithelial ovarian cancer is a highly lethal and aggressive gynecological malignancy. The high mortality rate is due in part to the fact that many advanced cancer patients become refractory to current chemotherapeutic agents, leading to tumor recurrence and death. However
Vicente Fresquet et al.
Blood, 123(26), 4111-4119 (2014-05-03)
Acquired resistance to targeted drugs is emerging as an obstacle to successful cancer treatment. Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. Based on its high affinity for BCL2, we studied potential mechanisms conferring
James Chih-Hsin Yang et al.
The Lancet. Oncology, 16(2), 141-151 (2015-01-16)
We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Previously untreated patients with EGFR mutation-positive stage IIIB or IV
Wei Qian et al.
Oncotarget, 5(12), 4180-4194 (2014-06-24)
Overcoming platinum drug resistance represents a major clinical challenge in cancer treatment. We discovered a novel drug combination using cisplatin and a class of thioquinazolinone derivatives including mdivi-1 (mitochondrial division inhibitor-1), that induces synergistic apoptosis in platinum resistant tumor cells
Exibir todos os documentos relacionados

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica